Request Demo

Last update 08 May 2025

B-823-10

Last update 08 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

2-[(4-methoxy-3-methyl-2-pyridylmethyl)-thio]-5-trifluoromethyl-(1H)-benzimidazole

Target

Proton pump

Action

inhibitors

Mechanism

Proton pump inhibitors

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

ALTANA Pharma AG

Active Organization

ALTANA Pharma AG

Inactive Organization-

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC16H14F3N3O2S

InChIKeyOWWKQFJLNQHYQS-UHFFFAOYSA-N

CAS Registry86604-68-4

100 Clinical Results associated with B-823-10

100 Translational Medicine associated with B-823-10

100 Patents (Medical) associated with B-823-10

Literatures (Medical) associated with B-823-10

01 Feb 2004·Amino AcidsQ3 · BIOLOGY

Inhibition of the L-dopa transport system in human epidermal Langerhans cells by omeprazole and its analogues

Q3 · BIOLOGY

Article

Author: Niels Bendsöe ; G Ronquist

L-3,4-dihydroxyphenylalanine (L-dopa) transport into human Langerhans cells (LC) occurs by a saturable mediation. This plasma membrane agency is, due to its characteristics, distinguishable from systems transporting other neutral, cationic and anionic amino acids into other cells and serves to catalyze the flow of L-dopa, only, into LC. The uphill operation of this L-dopa transport system is believed to occur by down-gradient countermigration of H(+). Due to the uniqueness of the L-dopa transport system, the widely used analogue inhibition approach was not applicable. Instead we studied omeprazole and its analogues in our search for suitable inhibitory candidates. Omeprazole and most of its analogues were indeed inhibitory in the concentration range 1-100 micromol/L. Conspicuously, the compounds with strongest polarity were least inhibitory. The inhibitory pattern displayed by omeprazole and the other analogues on L-dopa uptake in LC corresponded to some extent to what has been observed previously for purified H(+),K(+)-ATPase from tubulovesicles of the stomach. No effects of the inhibitors were registered on energy charge and lactate production of epidermal biopsies, nor were any gross alterations of ultrastructure of LC noticed.

01 Jun 1990·The Journal of Organic Chemistry

(H+-K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 3. Evidence for the involvement of a sulfenic acid in their reactions

Author: Senn-Bilfinger, Joerg ; Rainer, Georg ; Schaefer, Hartmann ; Sturm, Ernst ; Kohl, Bernhard ; Krueger, Uwe ; Klemm, Kurt ; Figala, Volker ; Blake, Timothy J.

The title compounds I (R = H, R¹ = CF₃, R² = R⁵ = H, R³ = Me, R⁴ = OMe; R = H, R¹ = OMe, R² = H, R³ = R⁵ = Me, R⁴ = OMe) undergo acid-induced transformations into the cyclic sulfenamides II via the putative sulfenic acids III.At high concentrations mixtures of II and thiolsulfinates IV (n = 1) were obtained.In contrast, I (R = CF₃, R¹ = H, R² = R³ = Me, R⁴ = OMe, R⁵ = H), which cannot form II, is completely transformed under similar conditions into IV (n = 1), the anhydride of III.The temperature-dependent equilibrium between II and IV (n = 1) and the kinetics of the ring opening of II by water provide evidence for the sulfenic acid III as an intermediate involved in the pH-dependent transformations of I.IV (n = 1) decompose mainly to the disulfides IV (n = 0) at a rate depending on the solvent and conditions and are also reduced to disulfides by thiols.

01 Jan 1989·Acta Chemica Scandinavica

Chemical Reactions of Omeprazole and Omeprazole Analogues. II. Kinetics of the Reaction of Omeprazole in the Presence of 2-Mercaptoethanol.

Author: Larsson, Sam ; Skånberg, Inger ; Brändström, Arne ; Erickson, Magnus ; Persson, Björn ; Löfberg, Ingalil ; Hagin, Inger ; Johansson, Svante ; Ohlson, Kristina ; Bergman, Nils-Åke ; Tekenbergs-Hjelte, Lija ; Alminger, Tomas ; Grundevik, Inger ; Hoffman, Kurt-Jürgen ; Lindberg, Per

The rate at which omeprazole (I) reacts with 2-mercaptoethanol is equal to the rate at which it converted to a sulfenamide.This reaction proceeds via two intermediates, a spiro compound and a sulfenic acid.A kinetic study of the reaction at different pH values revealed that the conversion to the spiro compound is the slowest step.It can be an uncatalyzed reaction, but can also be acid-catalyzed.Even the conversion of the spiro compound to the sulfenic acid can occur by an uncatalyzed reaction as well as by an acid-catalyzed one.The conversion of the sulfenic acid to the sulfenamide is very rapid.The rate constants for the different steps can usually be predicted.

100 Deals associated with B-823-10

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

B-823-10

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation